Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
GXH | Ann: GXH: Annual Shareholders' Meeting: Results | 01/08/24 | 0 | 78 | |||
|
|||||||
GXH | Ann: GXH: Annual Shareholders' Meeting: Speeches & Presentation | 01/08/24 | 0 | 85 | |||
|
|||||||
GXH | Ann: Green Cross Health Limited 2024 Annual Report | 26/06/24 | 0 | 195 | |||
|
|||||||
GXH | Ann: Green Cross Health Limited - Annual Shareholders' Meeting | 26/06/24 | 0 | 131 | |||
|
|||||||
GXH | Ann: D&O ongoing disclosure | 31/05/24 | 0 | 149 | |||
|
|||||||
GXH | Ann: Notice of issue of Ordinary Shares | 30/05/24 | 0 | 120 | |||
|
|||||||
GXH | Ann: GXH Annual Meeting & Director Nomination Dates | 30/05/24 | 0 | 112 | |||
|
|||||||
GXH | Ann: Green Cross Health Full Year Results to 31 March 2024 | 30/05/24 | 0 | 136 | |||
|
See All Discussions